Epigenome-Based Drug Repositioning in Acute Myeloid Leukemia

Adam S Brown

Department of Biomedical Informatics, Harvard Medical School
10 Shattuck St.
Boston, MA 02115.
adambrown@fas.harvard.edu

Chirag J Patel*

Department of Biomedical Informatics, Harvard Medical School
10 Shattuck St.
Boston, MA 02115.
(617) 432 1195
Chirag_Patel@hms.harvard.edu

**The author to whom correspondence should be addressed.*

ABSTRACT

Background. Repositioning approved drugs for the treatment of new indications is a promising avenue to reduce the burden of drug development. Most currently available computational methods based on molecular evidence can only utilize gene expression for repositioning despite a growing interest in the epigenome in human disease. We recently described a novel repositioning method, ksRepo, that enables investigators to move beyond microarray-based gene expression and utilize a variety of other sources of molecular evidence, such as DNA methylation differences.

Methods. We downloaded differential DNA methylation data from two publicly available acute myeloid leukemia (AML) datasets, a cancer with known, extensive epigenomic perturbations. We consolidated CpGs-level to non-directional gene-level differential methylation using Brown's correction to Fisher's method. We then used ksRepo, which ignores directionality in disease- and gene-drug associations, to mine the resulting prioritized gene lists and the Comparative Toxicogenomics Database (CTD) for predicted repositioning candidates.

Results. We successfully recovered four compounds that were significant ($FDR < 0.05$) in two AML datasets: cytarabine, alitretinoin, panobinostat, and progesterone. Cytarabine is the most commonly used frontline therapy for AML and alitretinoin, panobinostat, and progesterone have all been investigated for the treatment of AML.

Conclusions. Combining a method for consolidating CpG methylation to the gene level with ksRepo provides a pipeline for deriving drug repositioning hypotheses from differential DNA methylation. We claim that our platform can be extended to other diseases with epigenetic perturbations and to other epigenomic modalities, such as ChIP-seq.

INTRODUCTION

The process of nominating new indications for previously approved drugs, known as drug repositioning, has become increasingly attractive to industry and academia due to the substantial decrease in risk of unforeseen adverse events associated with compounds with known safety profiles [1–3]. A large number of computational approaches have been developed over the past 10 years that leverage molecular evidence to identify repositioning candidates, such as using differential gene expression [4–7]. Unfortunately, these methodologies are hindered by their need for specific data types, assay platforms, and data formats, preventing investigators from utilizing newer profiling technologies and expanding beyond gene expression. In particular, epigenomics is a key modality that has yet to be broadly utilized, in large part due to the lack of clear directionality at the gene level associated with differential DNA methylation and histone modifications; for instance, intra-exon DNA methylation can lead to upregulation or downregulation of gene expression depending on a variety of factors, including histone modifications [8,9].

Despite this complexity, epigenomic studies have been proposed as a promising data source for driving personalized medicine [10,11], but to our knowledge no methods have been published that allow the direct translation of epigenomic findings to drug repositioning. To address this unmet need, we developed a novel pipeline for identifying candidate repositioning candidates from epigenomic data, and in particular from DNA methylation data. We pair a widely used method to condense CpG-level DNA methylation to gene-level information with our previously described repositioning tool, ksRepo [12]. We demonstrate the utility of our method in AML using two independent genome-wide methylation datasets (see Figure 1). AML is the ideal case-study for our methodology, as recent work has shown that the AML epigenome evolves independently of mutational burden, and, furthermore, patients with AML respond well to DNA

demethylating agents (also known as “epigenetic drugs”) [13–16]. Using our pipeline, we recover significance for the most commonly used AML medication, cytarabine, as well as three other candidates with ongoing preclinical research in the AML space.

METHODS

GEO Dataset Processing

The datasets used in this study are GSE58477 and GSE63409, both of which are Illumina Infinium HumanMethylation450 chip-based (hereafter 450K) studies of AML [17,18]. GSE58477 contained data from a total of 62 patients with cytogenetically normal AML and 10 CD34+ normal bone marrow aspirate samples [17]. GSE63409 contained data from a total of 15 AML patients of varying FAB subtype classifications (M0: 1, M1: 2, M2: 2, M5: 5, Not Determined: 5) and five sorted, normal bone marrow aspirate samples [18]. Both GEO datasets were accessed through the NCBI GEO portal and analyzed using the GEO2R tool [19]. GEO2R uses the limma package in R [20], an analytic method originally designed for gene expression, which has been used to detect differential methylation [21,22]. As input for GEO2R, we classified each sample within a GEO series as either normal CD34+ bone marrow aspirate or leukemic blast (as indicated by either lack of engraftment only or by a combination of CD34- and lack of engraftment for GSE58477 and GSE63409 respectively). After classification we were left with 62:10 and 11:5 case:control ratios for GSE58477 and GSE63409 respectively.

Gene-level differential methylation using Fisher’s Method

To perform methylation-based repositioning, ksRepo requires a list of genes ranked according to their differential methylation. We therefore condensed the GEO2R output from CpG-level to gene-level differential methylation. Consolidating CpG-level significance values to gene-level values requires three steps: (1) identifying CpGs that are annotated to a given gene (obtained

from the manufacturer's website), (2) weighted combining of p-values from CpGs annotated to that gene, and (3) adjusting the resulting, combined p-value to take into account the high degree of correlation between CpGs within a single gene. We performed the weighted combination of p-values, and adjusted them using the *EmpiricalBrownsMethod* package in R [23,24].

EmpiricalBrownsMethod first combines CpG-level p-values into an omnibus statistic using Fisher's Method and then calculates an empirical p-value using the correlation structure of the CpGs in each GEO dataset [25]. Using this methodology, we condensed 407,090 individual CpGs into a list of 21,231 genes ranked by their degree of differential methylation (see Figure 1). Some CpGs lacked differential methylation estimates due to poor probe quality; for these CpGs, significance was set as the patient-level median significance for the other CpGs annotated to the same gene. For purposes of differential methylation calculations, all p-values were adjusted using the False Discovery Rate method [26]. After estimating gene-level significance, differentially methylated genes were taken to be those with FDR significance below 0.05. These differentially expressed genes were subjected to pathway enrichment analysis using the PANTHER classification system (PANTHER pathways were used, see [27]). In short, PANTHER contains manually curated pathway annotations for human genes, as well as built-in analytical tools for reporting statistical enrichment using fisher's exact test and gene-set enrichment; PANTHER was chosen due to the frequency of updates to its pathway annotations. In addition, PANTHER reports all enriched pathways using a strict family-wise error rate correction (to account for spurious findings or type 1 error), with significance deemed as Bonferroni-corrected p-value below 0.05 [28].

ksRepo repositioning and replication

To determine whether differential methylation-based repositioning is robust, we analyzed each dataset separately using ksRepo (package available for download at

<https://github.com/adam-sam-brown/ksRepo>, and described in [12]). ksRepo uses a modified Kolmogorov-Smirnov (KS) statistic that does not require directionality of effect, and calculates significance using resampling of compound-gene interaction lists. As our database of compound-gene interactions, we used the ksRepo Comparative Toxicogenomics Database (CTD) dataset, which is built into the ksRepo package. The CTD provides a curated resource that links small chemical entities to genes (e.g., gene or protein expression influences) from the scientific literature numerous model organisms and humans [29]. ksRepo contains a subset of the CTD containing human-derived interactions between 1,268 unique drugs and 18,041 unique human genes. Drugs in the ksRepo subset were chosen based on case-insensitive matches between CTD names and names/synonyms for FDA approved drugs downloaded from DrugBank [30]. We combined the ranked gene list from above with the CTD using ksRepo. ksRepo's output provides both the resampled and false discovery rate (FDR) adjusted p-value [26]. On the study-level, significant compounds were those for which the FDR was less than 0.05. Replicated hits were considered to be those compounds with significance in both methylation studies.

RESULTS AND DISCUSSION

Development of a pipeline for epigenome-based repositioning

In this study, we built on our previously developed tool, ksRepo, a drug repositioning methodology that enables investigators to use directionally agnostic, prioritized gene lists to nominate compounds as repositioning candidates. Removing the requirement for directionality of effect or association (e.g. up- or down-regulation of a gene) allows investigators to use complex molecular data, including DNA methylation. In a DNA methylation experiment, a single gene can have several CpG hyper- and hypomethylation events, which would yield both

negative and positive associations of DNA methylation with disease. Therefore, it is a challenge to summarize the overall “effect” direction of a gene with both negative and positive associations. As input for ksRepo, we consolidated over 400,000 CpGs to gene-level significance using Fisher’s omnibus statistic and corrected for the high degree of inter-CpG correlation using Brown’s Method (see Figure 1) [25]. Although we describe here a specific use-case of our pipeline for DNA methylation, our methodology can be adapted to other epigenomic signals, such as genome-wide ChIP-seq data from a variety of histone marks and other factors.

Epigenome-based repositioning using publicly available AML DNA methylation data

To assess the promise of our method, we used two, publicly available 450K DNA methylation datasets from GEO, both in AML [17,18]. Both studies noted clear patterns of hypo- and hypermethylation, with complex alterations in methylation taking place within genes, and especially within Wnt signaling genes and homeobox domain containing genes (HOX genes). Using our gene-level differential methylation consolidation technique, we found that GSE58477 and GSE63409 had 820 and 442 differentially expressed genes respectively (FDR < 0.05). Mirroring the results of the two GEO studies, we found that Wnt signaling genes, were significantly enriched in our method’s differentially methylated genes (PANTHER Wnt signaling pathway, Bonferroni-corrected $p < 2 \times 10^{-11}$ and $p < 3 \times 10^{-20}$ for GSE58477 and GSE63409 respectively, see Supplementary Files 1 and 2). This suggests that, although we lose some resolution by combining CpGs by gene, we do capture major trends in the AML methylation landscape.

Having verified that gene-level consolidation provides similar results to CpG-level differential methylation, we applied ksRepo independently to each GEO dataset. 1,075 drugs had at least one overlapping gene with those annotated in 450K chips and were tested using

ksRepo. We identified nine compounds with predicted FDR significance in only one of the datasets, and four that were significant in both. The four compounds significant in both datasets are presented in **Table 1** (results for all drugs are presented in Supplementary Table 1).

We posited that the most clear demonstration of utility for our method would be to correctly predict significance for the most commonly used AML therapy, cytarabine, which has remained the frontline therapy for over 30 years, and which is broadly effective against all subtypes of AML [31,32]. Indeed, our method did correctly identify cytarabine as highly significant in both datasets examined; however, our method did not identify either daunorubicin or idarubicin, two anthracycline chemotherapeutics that are commonly co-prescribed with cytarabine [31,33].

In addition to cytarabine, ksRepo nominated three novel compounds for use in AML: alitretinoin, panobinostat, and progesterone. Both alitretinoin, a geometric isomer of tretinoin currently used in the treatment of Acute Promyelocytic Leukemia (a subclass of AML) [34], and panobinostat, a histone deacetylase inhibitor commonly used in multiple myeloma [35], have been investigated for use in AML [36–39]. Lastly, while progesterone itself has not, to our knowledge, been suggested for AML treatment, a synthetic progestin, medroxyprogesterone acetate, has recently been suggested as a possible drug repositioning candidate for AML [40].

While our pipeline for epigenome-driven repositioning provided promising results for AML, it does have key limitations. First, as described above, removing the requirement for directionality (e.g. up- or down-regulation) provides substantial generality and allows for the use of CpG methylation data. However, such generalization does allow for the possibility that ksRepo candidates may have disease-exacerbating effects on their target genes; it is important, therefore, to perform *in vitro* and *in vivo* experiments to confirm which candidates are beneficial. Another possible drawback of non-directional repositioning is the possibility of missing

promising candidates; however, as previous studies using directional repositioning techniques failed to capture significance for cytarabine, and predicted fewer plausible repositioning candidates than ksRepo [41–43]. A second limitation is the requirement that methylation or other epigenomic marks are annotated to a specific gene or genes; however, in the future, as our understanding of extragenic enhancers and other epigenomic features improves, this limitation should diminish. Further investigation into and annotation of other epigenetic modifications will also help to broaden the available inputs for our method. Lastly, we acknowledge that the CTD may contain a relatively small proportion of the true compound-gene interaction space, and future versions of ksRepo will incorporate other data sources to broaden the available databases included in the ksRepo package.

CONCLUSIONS

In this study, we describe a pipeline for nominating drug repositioning candidates on the basis of differential methylation data. We combined a strategy for condensing CpG-level differential methylation to gene-level significance with our previously described drug repositioning tool, ksRepo. Unlike previously described methods of gene expression-based repositioning, which require up- or down-regulated gene or probe-level signals, our method is capable of leveraging complex gene-level differential methylation structure, for which there is often not a single directional effect. We applied our pipeline to discover repositioning candidates in AML, a disease with substantial epigenomic perturbations. We predicted significance for cytarabine, the most commonly prescribed AML medication, and identified three additional candidates with ongoing investigations for use in AML. Our method can be directly applied to other diseases with clear epigenetic perturbations and can be extended beyond DNA methylation to a variety of other epigenomic and molecular signals with complex or absent directionality.

FIGURE LEGENDS

Fig 1. Overview of the general pipeline design and exploratory AML analyses. Our general, DNA methylation-driven repositioning pipeline consists of (1) GEO2R differential methylation analysis, (2) consolidation of CpG-level significance to gene-level significance using Brown's Method, and (3) ksRepo computational drug repositioning analysis. For this study, we used two publicly available GEO (GSE58477 and GSE63409) datasets and identified four replicated repositioning candidates.

DECLARATIONS

Ethics approval and consent to participate. Not applicable.

Consent for publication. Not applicable.

Availability of data and material. AML datasets are publicly available through the Gene Expression Omnibus (Accession #'s GSE58477 and GSE63409). The ksRepo R package is available from github (<https://github.com/adam-sam-brown/ksRepo>).

Competing interests. The authors have no competing interests to declare.

Funding. ASB was supported by an National Institutes of Health (NIH) Training grant from the National Human Genome Research Institute (NHGRI), T32HG002295-12. CJP is supported by a National Institute of Environmental Health Sciences (NIEHS) R00 ES023504, R21 ES025052, a gift from Agilent Technologies, and a PhRMA fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Authors' contributions. ASB and CJP conceived of the study. ASB conducted all statistical analyses. ASB and CJP wrote the manuscript.

Acknowledgements. Not applicable.

REFERENCES

1. Readhead B, Dudley J. Translational Bioinformatics Approaches to Drug Development. *Adv. Wound Care*. 2013;2:470–89.
2. Shameer K, Readhead B, Dudley JT. Computational and experimental advances in drug repositioning for accelerated therapeutic stratification. *Curr. Top. Med. Chem*. 2015;15:5–20.
3. Li J, Zheng S, Chen B, Butte AJ, Swamidass SJ, Lu Z. A survey of current trends in computational drug repositioning. *Brief. Bioinform.* [Internet]. 2015; Available from: <http://dx.doi.org/10.1093/bib/bbv020>
4. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. *Science*. 2006;313:1929–35.
5. Gottlieb A, Stein GY, Ruppin E, Sharan R. PREDICT: a method for inferring novel drug indications with application to personalized medicine. *Mol. Syst. Biol*. 2011;7:496.
6. Menden MP, Iorio F, Garnett M, McDermott U, Benes CH, Ballester PJ, et al. Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties. *PLoS One*. 2013;8:e61318.
7. Huang H, Nguyen T, Ibrahim S, Shantharam S, Yue Z, Chen JY. DMAP: a connectivity map database to enable identification of novel drug repositioning candidates. *BMC Bioinformatics*. 2015;16 Suppl 13:S4.
8. Kulis M, Queirós AC, Beekman R, Martín-Subero JI. Intragenic DNA methylation in transcriptional regulation, normal differentiation and cancer. *Biochim. Biophys. Acta*. 2013;1829:1161–74.
9. Lawrence M, Daujat S, Schneider R. Lateral Thinking: How Histone Modifications Regulate Gene Expression. *Trends Genet*. 2016;32:42–56.
10. Miozzo M, Vaira V, Sirchia SM. Epigenetic alterations in cancer and personalized cancer treatment. *Future Oncol*. 2015;11:333–48.
11. Yan W, Herman JG, Guo M. Epigenome-based personalized medicine in human cancer. *Epigenomics*. 2016;8:119–33.
12. Brown AS, Kong SW, Kohane IS, Patel CJ. ksRepo: a generalized platform for computational drug repositioning. *BMC Bioinformatics*. 2016;17:78.
13. Roboz GJ. Epigenetic targeting and personalized approaches for AML. *Hematology Am. Soc. Hematol. Educ. Program*. 2014;2014:44–51.
14. Yun S, Vincelette ND, Abraham I, Robertson KD, Fernandez-Zapico ME, Patnaik MM. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials. *Clin. Epigenetics*. 2016;8:68.
15. Wouters BJ, Delwel R. Epigenetics and approaches to targeted epigenetic therapy in acute

myeloid leukemia. *Blood*. 2016;127:42–52.

16. Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T, Rapaport F, et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. *Nat. Med.* [Internet]. 2016; Available from: <http://dx.doi.org/10.1038/nm.4125>

17. Qu Y, Lennartsson A, Gaidzik VI, Deneberg S, Karimi M, Bengtzen S, et al. Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes. *Epigenetics*. 2014;9:1108–19.

18. Jung N, Dai B, Gentles AJ, Majeti R, Feinberg AP. An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis. *Nat. Commun.* 2015;6:8489.

19. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets—update. *Nucleic Acids Res.* 2013;41:D991–5.

20. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* 2015;43:e47.

21. Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. *Bioinformatics*. 2014;30:1363–9.

22. Klein H-U, Hebestreit K. An evaluation of methods to test predefined genomic regions for differential methylation in bisulfite sequencing data. *Brief. Bioinform.* [Internet]. 2015; Available from: <http://dx.doi.org/10.1093/bib/bbv095>

23. Development Core Team R. R: A Language and Environment for Statistical Computing. Vienna, Austria: the R Foundation for Statistical Computing. 2011;

24. Poole W. EmpiricalBrownsMethod: Uses Brown’s method to combine p-values from dependent tests [Internet]. 2016. Available from: <https://github.com/IlyaLab/CombiningDependentPvaluesUsingEBM.git>

25. Brown MB. 400: A Method for Combining Non-Independent, One-Sided Tests of Significance. *Biometrics*. [Wiley, International Biometric Society]; 1975;31:987–92.

26. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J. R. Stat. Soc. Series B Stat. Methodol.* Wiley; 1995;57:289–300.

27. Mi H, Muruganujan A, Casagrande JT, Thomas PD. Large-scale gene function analysis with the PANTHER classification system. *Nat. Protoc.* 2013;8:1551–66.

28. Wadi L, Meyer M, Weiser J, Stein LD, Reimand J. Impact of outdated gene annotations on pathway enrichment analysis. *Nat. Methods*. 2016;13:705–6.

29. Davis AP, Grondin CJ, Lennon-Hopkins K, Saraceni-Richards C, Sciaky D, King BL, et al. The Comparative Toxicogenomics Database’s 10th year anniversary: update 2015. *Nucleic*

Acids Res. 2015;43:D914–20.

30. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. *Nucleic Acids Res.* 2006;34:D668–72.

31. Tauro S. The blind men and the AML elephant: can we feel the progress? *Blood Cancer J.* 2016;6:e424.

32. Yamada S, Hongo T, Okada S, Watanabe C, Fujii Y, Ohzeki T. Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia. *Leukemia.* 2001;15:1892–7.

33. Wang J, Yang Y-G, Zhou M, Xu J-Y, Zhang Q-G, Zhou R-F, et al. Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia. *PLoS One.* 2013;8:e60699.

34. Coombs CC, Tavakkoli M, Tallman MS. Acute promyelocytic leukemia: where did we start, where are we now, and the future. *Blood Cancer J.* 2015;5:e304.

35. Liu J-D, Sun C-Y, Tang L, Wu Y-Y, Wang Q-Y, Hu B, et al. Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review. *Sci. Rep.* 2016;6:27361.

36. Hofmann WK, Kell WJ, Fenaux P, Castaigne S, Ganser A, Chomienne C, et al. Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study. *Leukemia.* 2000;14:1583–8.

37. Koistinen P, Zheng A, Säily M, Siitonen T, Mäntymaa P, Savolainen E-R. Superior effect of 9-cis retinoic acid (RA) compared with all-trans RA and 13-cis RA on the inhibition of clonogenic cell growth and the induction of apoptosis in OCI/AML-2 subclones: is the p53 pathway involved? *Br. J. Haematol.* 2002;118:401–10.

38. Wang CL, Ding BJ, Jiang L, Yin CX, Zhong QX, Yu GP, et al. Increased expression of amyloid precursor protein promotes proliferation and migration of AML1/ETO-positive leukemia cells and be inhibited by panobinostat. *Neoplasma.* 2015;62:864–71.

39. Qi W, Zhang W, Edwards H, Chu R, Madlambayan GJ, Taub JW, et al. Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo. *Cancer Biol. Ther.* 2015;16:1784–93.

40. Southam AD, Khanim FL, Hayden RE, Constantinou JK, Koczula KM, Michell RH, et al. Drug Redeployment to Kill Leukemia and Lymphoma Cells by Disrupting SCD1-Mediated Synthesis of Monounsaturated Fatty Acids. *Cancer Res.* 2015;75:2530–40.

41. Hassane DC, Guzman ML, Corbett C, Li X, Abboud R, Young F, et al. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. *Blood.* 2008;111:5654–62.

42. Manzotti G, Parenti S, Ferrari-Amorotti G, Soliera AR, Cattelani S, Montanari M, et al.

Monocyte-macrophage differentiation of acute myeloid leukemia cell lines by small molecules identified through interrogation of the Connectivity Map database. *Cell Cycle*. 2015;0.

43. Lara-Castillo MC, Cornet-Masana JM, Etxabe A, Banús-Mulet A, Torrente MÁ, Nomdedeu M, et al. Repositioning of bromocriptine for treatment of acute myeloid leukemia. *J. Transl. Med.* 2016;14:261.

Case/Control Disease GEO Datasets

Genome-Wide DNA Methylation

Infinium HumanMethylation450 chip

Differential Methylation

GEO2R, Limma Based

407,090 Annotated CpGs

Ranked by Differential
Methylation

Gene-Level Aggregation

Empirical Browns Method

21,231 Genes

Ranked by Brown's
Method P-value

Repositioning Prediction

ksRepo using CTD Data
(Strict FDR < 0.05 Cutoff)

**Single Dataset
FDR Significant
Compounds**

Replication

Repositioning Candidates

General
Pipeline

Study Specific